Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naïve (extensive disease) or have a sensitive relapse
Phase 2
- Conditions
- small cell lung cancer1003866610029107
- Registration Number
- NL-OMON33984
- Lead Sponsor
- European Organisation for Research in Treatment of Cancer (EORTC)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Histologically proven SCLC
Chemo naive or sensitive relapse
Measurable disease
Normal organ function
Exclusion Criteria
Myocardal infarction, unstable angina, congestive heart failure, cerobrovascular accident or pulmonary embolus within 6 months
NCICTCAE grade 3 hemorrhage within 4 weeks
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Disease control rate (number of CR+PR+SD) at 4 weeks </p><br>
- Secondary Outcome Measures
Name Time Method <p>Response rate<br /><br>Duration of progression free survival<br /><br>Duration of response<br /><br>Duration of survival<br /><br>Toxicity</p><br>